[{"id":"3d1b2e02-0b22-495b-9eec-788ad524f8cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT01726738","created_at":"2021-01-18T07:32:30.279Z","updated_at":"2025-02-25T13:10:32.240Z","phase":"Phase 2","brief_title":"LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations","source_id_and_acronym":"NCT01726738","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" PTEN • MAP3K8","pipe":" | ","alterations":" BRAF V600E • BRAF mutation • BRAF V600 • BRAF V600K","tags":["PTEN • MAP3K8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF mutation • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 04/04/2013","start_date":" 04/04/2013","primary_txt":" Primary completion: 11/03/2017","primary_completion_date":" 11/03/2017","study_txt":" Completion: 09/17/2020","study_completion_date":" 09/17/2020","last_update_posted":"2020-11-23"}]